12/19
08:32 am
xoma
XOMA Corp - 8.375% DP PFD B declares $0.5234 dividend [Seeking Alpha]
Low
Report
XOMA Corp - 8.375% DP PFD B declares $0.5234 dividend [Seeking Alpha]
12/19
07:30 am
xoma
XOMA Royalty Declares Quarterly Preferred Stock Dividends
Low
Report
XOMA Royalty Declares Quarterly Preferred Stock Dividends
12/13
12:19 pm
xoma
XOMA Co. (NASDAQ: XOMA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $123.00 price target on the stock.
Low
Report
XOMA Co. (NASDAQ: XOMA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $123.00 price target on the stock.
12/2
11:37 am
xoma
XOMA Co. (NASDAQ: XOMA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $123.00 price target on the stock, up previously from $117.00.
Low
Report
XOMA Co. (NASDAQ: XOMA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $123.00 price target on the stock, up previously from $117.00.
12/2
07:30 am
xoma
XOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its Portfolio
Medium
Report
XOMA Royalty Acquires Pulmokine for $20 Million Adding the Royalty and Milestone Interest in Seralutinib, a Phase 3 Asset, to Its Portfolio
11/7
07:30 am
xoma
XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities
Low
Report
XOMA Royalty Reports Third Quarter 2024 Financial Results and Highlights Recent Activities
10/23
08:18 am
xoma
XOMA Co. (NASDAQ: XOMA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $117.00 price target on the stock.
Low
Report
XOMA Co. (NASDAQ: XOMA) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $117.00 price target on the stock.
10/22
08:00 am
xoma
XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience
Low
Report
XOMA Royalty Significantly Expands its Royalty and Milestone Portfolio with the Addition of Over 60 Early-Stage Programs from Twist Bioscience
9/23
06:30 am
xoma
Zevra’s MIPLYFFA™ (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC)
Low
Report
Zevra’s MIPLYFFA™ (arimoclomol) Receives Approval from U.S. Food and Drug Administration for Use in Patients with Niemann-Pick Disease Type C (NPC)
9/23
05:30 am
xoma
XOMA Royalty Declares Quarterly Preferred Stock Dividends
Low
Report
XOMA Royalty Declares Quarterly Preferred Stock Dividends